Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 9/20 | 0.35 |
| ▸ | FEN1 | P39748 | 9/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22019992 | 0.81 | HPGD (0.39) | ALDH1A1SMN1; SMN2MAPTLMNAKDM4E | |
| SCHEMBL4972879 | 0.80 | NSD2 (0.41) | ALDH1A1MCL1SMN1; SMN2MAPTLMNA | |
| SCHEMBL8477444 | 0.76 | DAO (0.46) | ALDH1A1MCL1SMN1; SMN2MAPTLMNA | |
| SCHEMBL14077463 | 0.73 | ALDH1A1 (0.35) | ALDH1A1MCL1SMN1; SMN2MAPTLMNA | |
| SCHEMBL18701587 | 0.71 | MCL1 (0.33) | MCL1RAB9AMAPK1 | |
| SCHEMBL1790814 | 0.69 | CNR1 (0.51) | ALDH1A1MCL1SMN1; SMN2MAPTLMNA | |
| SCHEMBL24429413 | 0.68 | CCR2 (0.59) | ALDH1A1 | |
| SCHEMBL1523222 | 0.67 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTLMNAMEN1 | |
| SCHEMBL21962637 | 0.67 | ALDH1A1 (0.31) | ALDH1A1CYP3A4CYP2C9MAPK1 | |
| SCHEMBL18077979 | 0.67 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-3880660-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| EP-3880659-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| US-7358257-B2 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1734041-A2 | Platelet ADP receptor inhibitors | Portola Pharmaceuticals, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1412364-B1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARM INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060194795-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-7056926-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20050228029-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, particularly those diseases related to thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-6906063-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1412364-A1 | PLATELET ADP RECEPTOR INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003011872-A1 | PLATELET ADP RECEPTOR INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | ALEXION PHARMACEUTICALS, INC. | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 1972/4885MCL1 4130/4885SMN1; SMN2 2608/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ALDH1A1 1999/4885MCL1 4130/4885SMN1; SMN2 2744/4885 |
| US-20050228029-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, particularly those diseases related to thrombosis | PIGS, ABCC9, TBXA2R | ALDH1A1 1546/4885MCL1 1981/4885SMN1; SMN2 2419/4885 |
| US-20020077486-A1 | For therapy and prophylaxis of thrombosis in a mammal | PIGS, TBXA2R, GP6 | ALDH1A1 1356/4885MCL1 2265/4885SMN1; SMN2 2806/4885 |
| US-20060194795-A1 | sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents | PIGS, ABCC9, TBXA2R | ALDH1A1 1437/4885MCL1 2112/4885SMN1; SMN2 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.